Dysmenorrhea in Emergency Medicine Medication

  • Author: Andre Holder, MD; Chief Editor: Pamela L Dyne, MD   more...
 
Updated: Apr 15, 2011
 

Medication Summary

Treatment of dysmenorrhea is aimed at providing symptomatic relief as well as inhibiting the underlying processes that cause symptoms.

NSAIDs reduce prostaglandin production via cyclooxygenase inhibition and are used as first-line therapy for both primary and secondary dysmenorrhea. If taken early enough and in sufficient quantity, they are extremely successful in alleviating menstrual pain. In the ED setting, patients who do not respond to NSAIDs may require treatment with narcotics for pain control. Patients whose symptoms are not relieved by NSAIDs are very likely to have underlying pelvic pathology such as endometriosis.

In a study comparing montelukast, a leukotriene-receptor antagonist, to placebo in patients with dysmenorrhea, montelukast was effective in reducing pain.[12] Clinicians may consider this as an alternative to hormonal therapy or in lieu of NSAIDs.

COX-2 specific inhibitors have also proven effective in relieving menstrual pain. Their selectivity reduces the GI symptoms caused by inhibition of the COX-1 receptor. However, recent clinical trials have raised their cardiovascular safety profiles into question. As a result, some of these agents are no longer available.

Simple analgesics, such as aspirin and acetaminophen, may also be useful, especially when NSAIDs are contraindicated.

Oral contraceptives, which block monthly ovulation and may decrease menstrual flow, may also relieve symptoms. One recent update of a CochraneDatabase of Systematic Reviews article showed some evidence of symptomatic benefit in patients with primary dysmenorrhea, though no specific preparation showed superiority over another.[13]

Certain dietary supplements may be effective, though their effectiveness has only been demonstrated in small clinical trials. Thiamine, fish oil, pyridoxine, magnesium, and vitamin E are examples.[3, 14]

Next

Nonsteroidal anti-inflammatory agents

Class Summary

These drugs are highly effective in treating dysmenorrhea, especially when they are started before the onset of menses and continued through day 2. They are readily available, relatively inexpensive, and have a low side effect profile when used cautiously and in those who have no contraindications.

Ibuprofen (Ibuprin, Advil, Motrin)

 

DOC for treatment of mild to moderate pain, if not contraindicated. Inhibits inflammatory reactions and pain, probably by decreasing activity of the enzyme cyclooxygenase, which results in inhibition of prostaglandin synthesis.

Naproxen (Anaprox, Naprelan, Naprosyn, Aleve)

 

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in decrease of prostaglandin synthesis. Cost is approximately $3.00/d compared with $0.14/d for generic ibuprofen.

Diclofenac (Cataflam, Voltaren)

 

Designated chemically as 2-[(2,6-dichlorophenyl) amino] benzene acetic acid, monosodium salt, with an empirical formula of C14 H10 Cl2 NO2 NA. One of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacologic studies. Believed to inhibit the enzyme cyclooxygenase, which is essential in prostaglandin biosynthesis. Can cause hepatotoxicity; hence, liver enzymes should be monitored in first 8 weeks of treatment. Rapidly absorbed; metabolism occurs in liver by demethylation, deacetylation, and glucuronide conjugation. Delayed-release, enteric-coated form is diclofenac sodium, and immediate-release form is diclofenac potassium. Has relatively low risk for bleeding GI ulcers.

Hydrocodone and acetaminophen (Vicodin, Lorcet-HD, Lortab)

 

Drug combination indicated for moderate to severe pain.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Andre Holder, MD  Staff Physician, Departments of Emergency Medicine and Internal Medicine, Jacobi Medical Center

Andre Holder, MD, is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and National Medical Association

Disclosure: Nothing to disclose.

Coauthor(s)

Laurel D Edmundson, MD  Clinical Assistant Instructor of Emergency Medicine, Resident, Department of Emergency Medicine, Kings County Hospital Center, Brooklyn

Laurel D Edmundson, MD is a member of the following medical societies: American Medical Association and Medical Society of the State of New York

Disclosure: Nothing to disclose.

Mert Erogul, MD  Assistant Professor of Emergency Medicine, University Hospital of Brooklyn: Consulting Staff, Department of Emergency Medicine, Kings County Hospital Center

Mert Erogul, MD is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Steven A Conrad, MD, PhD  Chief, Department of Emergency Medicine; Chief, Multidisciplinary Critical Care Service, Professor, Department of Emergency and Internal Medicine, Louisiana State University Health Sciences Center

Steven A Conrad, MD, PhD is a member of the following medical societies: American College of Chest Physicians, American College of Critical Care Medicine, American College of Emergency Physicians, American College of Physicians, International Society for Heart and Lung Transplantation, Louisiana State Medical Society, Shock Society, Society for Academic Emergency Medicine, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Mark Zwanger, MD, MBA  Assistant Professor, Department of Emergency Medicine, Jefferson Medical College of Thomas Jefferson University

Mark Zwanger, MD, MBA is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and American Medical Association

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Pamela L Dyne, MD  Professor of Clinical Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

References
  1. Durain D. Primary dysmenorrhea: assessment and management update. J Midwifery Womens Health. Nov-Dec 2004;49(6):520-8. [Medline].

  2. Proctor ML, Murphy PA, Pattison HM, Suckling J, Farquhar CM. Behavioural interventions for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. Jul 18 2007;CD002248. [Medline].

  3. French L. Dysmenorrhea. Am Fam Physician. Jan 15 2005;71(2):285-91. [Medline].

  4. Baines PA, Allen GM. Pelvic pain and menstrual related illnesses. Emerg Med Clin North Am. Aug 2001;19(3):763-80. [Medline].

  5. Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ. May 13 2006;332(7550):1134-8. [Medline].

  6. Kalish GM, Patel MD, Gunn ML, Dubinsky TJ. Computed tomographic and magnetic resonance features of gynecologic abnormalities in women presenting with acute or chronic abdominal pain. Ultrasound Q. Sep 2007;23(3):167-75. [Medline].

  7. Kamaya A, Shin L, Chen B, Desser TS. Emergency gynecologic imaging. Semin Ultrasound CT MR. Oct 2008;29(5):353-68. [Medline].

  8. Walker CK, Wiesenfeld HC. Antibiotic therapy for acute pelvic inflammatory disease: the 2006 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. Apr 1 2007;44 Suppl 3:S111-22. [Medline].

  9. Houry D, Abbott JT. Ovarian torsion: a fifteen-year review. Ann Emerg Med. Aug 2001;38(2):156-9. [Medline].

  10. Levy BS, Apgar BS, Surrey ES, Wysocki S. Diagnosis and management: chronic pelvic pain and endometriosis. OBG Management. 2007/03;supp:S3-S13.

  11. Parker JD, Leondires M, Sinaii N, Premkumar A, Nieman LK, Stratton P. Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis. Fertil Steril. Sep 2006;86(3):711-5. [Medline].

  12. Fujiwara H, Konno R, Netsu S, et al. Efficacy of montelukast, a leukotriene receptor antagonist, for the treatment of dysmenorrhea: a prospective, double-blind, randomized, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol. Feb 2010;148(2):195-8. [Medline].

  13. Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev. Apr 15 2009;CD002120. [Medline].

  14. Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG. Apr 2005;112(4):466-9. [Medline].

  15. Latthe P, Mignini L, Gray R, Hills R, Khan K. Factors predisposing women to chronic pelvic pain: systematic review. BMJ. Apr 1 2006;332(7544):749-55. [Medline].

  16. [Best Evidence] Witt CM, Reinhold T, Brinkhaus B, Roll S, Jena S, Willich SN. Acupuncture in patients with dysmenorrhea: a randomized study on clinical effectiveness and cost-effectiveness in usual care. Am J Obstet Gynecol. Feb 2008;198(2):166.e1-8. [Medline].

  17. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol. Nov 15 1982;144(6):655-60. [Medline].

  18. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol. Apr 1996;174(4):1335-8. [Medline].

Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.